ESHRE's good practice guide for cross-border reproductive care for centers and practitioners by Shenfield, Françoise et al.
ESHRE PAGES
ESHRE’s good practice guide
for cross-border reproductive care
for centers and practitioners†
F. Shenﬁeld1, G. Pennings2, J. De Mouzon3, A.P. Ferraretti4,
and V. Goossens5, on behalf of the ESHRE Task Force ‘Cross Border
Reproductive Care’ (CBRC)
1University College London Hospitals Trust, Reproductive Medicine Unit, London, UK 2Department of Philosophy, Bioethics Institute Ghent
(BIG) Ghent University, Ghent, Belgium 3Cochin-Saint-Vincent De Paul, Service de Gyne´cologie Obste´trique II et de Me´decine de la
Reproduction, Paris, France 4S.I.S.M.E.R. s.r.l., Reproductive Medicine Unit, Bologna, Italy 5ESHRE Central Ofﬁce, Grimbergen, Belgium
Submitted on February 23, 2011; resubmitted on February 23, 2011; accepted on March 2, 2011
abstract: This paper outlines ESHRE’s guidance for centers and physicians providing fertility treatment to foreign patients. This guide
aims to ensure high-quality and safe assisted reproduction treatment, taking into account the patients, their future child and the interests of
third-party collaborators such as gametes donors and surrogates. This is achieved by including considerations of equity, safety, efﬁciency,
effectiveness (including evidence-based care), timeliness and patient centeredness.
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Introduction and background
Cross-border reproductive care (CBRC) refers to a widespread
phenomenon where infertile patients or collaborators (such as egg
donors or potential surrogates) cross international borders in order
to obtain or provide reproductive treatment outside their home
country.
The reasons for traveling vary between countries, but the most
common reason is law evasion when the technique is either forbidden
per se or when a particular group is excluded from treatment. There
may be other access limitations at home such as long waiting lists.
Other reasons for travelling are better quality of care and cheaper
treatment (Pennings et al., 2008a; Shenﬁeld et al., 2010).
The ideal is fair access to fertility treatment at home for all patients.
This ideal should be promoted at all levels (Pennings et al., 2008b).
However, when for some reason, treatment at home is not possible
or not available, CBRC is a solution that enhances patient’s autonomy.
Furthermore, it ﬁts with the principle of freedom of movement of
patients within Europe (EU proposal directive, 2008).
This Good Practice Guide (GPG) provides guidance for centers and
physicians treating foreign patients. The guidelines included here can
help regulators and policy-makers create a framework to enable
centers to abide by these rules. Although in principle, the care of
foreign and local patients should be the same, and ﬁt the best possible
standards, there is evidence that this is not always the case.
The aim is to ensure high-quality assisted reproduction treatment,
as deﬁned by the European Union criteria for good quality medical
treatment (European Union Council, 2006), and the ESHRE position
paper on Good Clinical Treatment in Assisted Reproduction
(ESHRE, 2008, www.eshre.eu).
This GPG focuses on the relevant principles for respectively
patients, donors, future children, surrogates and professionals. The
operational principles to be considered include equity, safety, efﬁ-
ciency, effectiveness (including evidence-based care), timeliness and
patient centeredness. These principles are all equally important and
have no ﬁxed order of priority.
1. Equity in CBRC
1.1 Patients
Equity implies that similar protocols and fees are applied and that the
same information, counseling and psychological support is provided
for foreign as for national patients. Any difference between local and
foreign patients should be justiﬁed—for instance, the extra cost for
interpreters.
Crossing borders may also lead to increased shortage of scarce
resources in the visited country to the detriment of local citizens.
Clinics may want to introduce a system for fair allocation of scarce
resources that takes into account the local needs such as a
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maximum number (or percentage) of treatments provided to foreign
patients.
1.2 Donors
Donors should receive similar care to patients and local donors. No
distinctions should be introduced based on their origin and/or motiv-
ation. National and foreign donors should be offered comparable
compensation and the recruitment criteria should be the same.
2. Quality, safety and
evidence-based care in
cross border treatment
2.1 Patients
Quality, safety and evidence-based care provision should lead to
minimal risks with a maximum chance of pregnancy. Patients should
receive clear information about necessary investigations and their
cost, about waiting list times and the expected time they will have
to spend outside their country. Quality also implies that patients are
not subjected to unnecessary procedures. Communication and collab-
oration between the clinical team in the home country and the team
abroad should minimize the need for repeat tests, which are both
expensive and cumbersome for the patients.
The provision of the accurate success rate of the center is impor-
tant to enable patients to decide on a treatment plan. Furthermore,
patients should be informed whether the treatment offered is
(ideally) evidence-based, current practice or following an ‘experimen-
tal protocol’. In the latter case, equity demands that foreign patients
are given the same beneﬁts and submitted to the same rules as
local patients: if they are offered treatment which is still research for
instance, the consent and cost should be the same as for local
patients.
In the case of gamete donation, it is essential to follow the rec-
ommendations of the EU tissues directive, with special regard to the
screening process and the non-commercialization conditions.
In some cases, deviations from standard management may be
appropriate (e.g. conversion from IUI to IVF during treatment cycle;
use of techniques such as ICSI or blastocyst transfer). However,
aggressive treatment that may endanger the woman’s health by, for
instance, disproportionate stimulation and deviations from the rules
for embryo transfer are not justiﬁed (ESHRE good clinical practice).
Treatment options may also differ from local patients (stimulation
from mild to standard) according to whether patients are returning.
The ability to cryopreserve oocytes and embryos is an important con-
sideration which should be discussed beforehand. Also a possible
transfer of the gametes or embryos to a clinic at home has to be
considered.
2.2 Donors
It is essential to propose a stimulation cycle that minimizes the health
risk for the oocyte donors. Reliable data regarding risks are scarce,
especially in the case of repeated donation. Donors may present
themselves several times at the same center or at different centers.
In order to obtain information on repeated donations and to be
able to verify legal restrictions on donations, it is essential ﬁrstly to
establish national registers of gametes donors, and secondly for
centers to participate in the collection of national or international data.
In order to prevent the abuse of donors coming from abroad, one
should avoid using intermediate agencies, which may lead to violations
of the rules of good clinical practice and, in the worst case, to trafﬁck-
ing. Post-donation care should be provided to the best possible stan-
dards at home or abroad.
Screening for sexually transmitted disease and genetic disease should
be similar to national patients (application of the EU Tissue directive).
2.3 Surrogacy
Single embryo transfer is the only acceptable option. Continuity of
care during pregnancy and childbirth must be planned prior to starting
the surrogacy cycle.
The provision of legal advice about local rules is the remit of the
local practitioner, or if not possible, through referral to appropriate
local legal advisors. The intended parents should try to obtain accurate
information about their own national situation before embarking on
the process. Known legal problems or possible conﬂicts with the
law in the home country should be explained to the patients.
2.4 Children
Treatment should abide by the rules of ‘good clinical treatment in
ART’ (ESHRE, 2008, www.eshre.eu). These rules state that ‘the
decline in the number of multiple births can be regulated only with
a reduction of the number of embryos transferred. This restrictive
embryo transfer policy could be accepted as the only means of elim-
inating high order multiple gestations’. Indeed, in spite of the mounting
evidence that repeated single embryo transfer gives the same accumu-
lated chance of pregnancy as multiple embryo transfer, many couples
ﬁnd it difﬁcult to accept. Travelling couples may be even more reluc-
tant to accept that because of the extra cost and stress of travelling
several times. This endangers the welfare of the future child(ren).
Foreign patients should have the same stimulation protocol as local
patients, taking into account age and previous stimulations. When
donor oocytes are used, embryo transfer must be limited to two
embryos.
Follow up of ART children, whether conceived after treatment at
home or abroad, should be encouraged.
2.5 Professionals
Collaboration between doctors: If a home practitioner refers the
patient to a speciﬁc clinic, the practitioner shares a responsibility for
the general standards used in that center (such as the complication
rate).The speciﬁc treatment of the individual patient abroad remains
the responsibility of the local professional team.
Collaboration between the home practitioner and the receiving
center offers the best chance of optimal care for the cross border
patient. The only countries where this may pose a problem is
where it is forbidden for doctors to give information about alternatives
that are not legal in the country of residence of the patient.
Good communication in both directions includes details of previous
investigations and treatment (stimulation dose, response, etc.).
Patients should be given copies of their medical ﬁles both by the
home practitioners when they go abroad and by the practitioners
abroad when they return home.
1626 Shenﬁeld et al.
 at Biom
edische Bibliotheek on June 26, 2011
hum
rep.oxfordjournals.org
D
ow
nloaded from
 
3. Patient involvement
Professionals should take into consideration the speciﬁc circumstances
of foreign patients by adapting their practical management. It may be
difﬁcult to ensure that patients understand enough to give appropriate
consent. This may be particularly difﬁcult when there is no common
language. Given the number of nationalities of the foreign patients, it
is impossible to have translators in all possible languages. This notwith-
standing, counseling and psychological support should be available in a
language understood by the patients. If a reasonable understanding
cannot be guaranteed, it is recommended not to treat the patient.
Due to the extra pressure on foreign patients, there is an increased
risk of ill-considered decisions. For instance, a rapid shift to third party
conception in case of failed fertilization, or the acceptance of double
rather than single embryo transfer. In all instances, however, we rec-
ommend that treatment offered is compatible with ESHRE ‘good clini-
cal treatment’ position paper’s recommendations.
Doctors in receiving centers should ask patients to obtain the relevant
details of their previous investigations and care, especially when there is
no possibility of direct exchange of information between the doctors.
Similarly, professionals abroad should provide the appropriate rel-
evant information to the patients returning home in order to optimize
their care at home.
4. Redress
The clinic should provide the name of their ombudsman or the person
to whom complaints should be addressed.
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